Burosumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Burosumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetFGF 23
Clinical data
Trade namesCrysvita
Other namesKRN23
ATC code
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6388H9904N1700O2006S46
Molar mass144090.15 g·mol−1

Burosumab (INN, trade name Crysvita) known as KRN23 is a human monoclonal antibody designed for the treatment of X-linked hypophosphatemia.[1][2][3] Burosumab was approved by the FDA for its intended purpose, in patients aged 1 year and older, on 17 April 2018.[4] The FDA approval fell under both the breakthrough therapy and orphan drug designations.[4]

This drug was developed by Ultragenyx and is in a collaborative license agreement with Kyowa Hakko Kirin.[5]

While burosumab is effective for the treatment of X-linked hypophosphatemia, the National Institute for Health and Care Excellence in England and Wales initially raised concerns regarding the incremental cost-effectiveness of the new treatment[6] but the drug is available through a simple discount scheme. [7]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Burosumab, American Medical Association.[permanent dead link]
  2. ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2): 255.
  3. ^ "Burosumab (KRN23) for X-Linked Hypophosphatemia (XLH)" (PDF). n.d. Archived from the original (PDF) on 2018-04-18. Retrieved 2018-04-18.
  4. ^ a b "FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia" (Press release). FDA. 17 April 2018.
  5. ^ "Collaboration with Ultragenyx to Develop and Commercialize KRN23 for X-linked Hypophosphatemia" (Press release). Kyowa Kirin. 4 September 2013. Retrieved 2018-04-17.
  6. ^ "U.K. cost watchdogs turn away rare disease med Crysvita".
  7. ^ "1 Recommendations | Burosumab for treating X-linked hypophosphataemia in children and young people | Guidance | NICE". www.nice.org.uk. Retrieved 2019-06-14.